Skip to content

Research at St Andrews

Greater early bactericidal activity at higher rifampicin doses revealed by modeling and clinical trial simulations

Research output: Contribution to journalArticle

DOI

Open Access Status

  • Embargoed (until 28/04/19)

Author(s)

Robin J Svensson, Elin M Svensson, Rob E Aarnoutse, Andreas H Diacon, Rodney Dawson, Stephen H Gillespie, Mischka Moodley, Martin J Boeree, Ulrika S H Simonsson

School/Research organisations

Abstract

Background The currently recommended rifampicin dose (10 mg/kg) for treating tuberculosis is suboptimal. The PanACEA HIGHRIF1 trial evaluated the pharmacokinetics and early bactericidal activity of rifampicin doses of up to 40 mg/kg. Conventional statistical analyses revealed no significant exposure-response relationship. Our objectives were to explore the exposure-response relationship for high-dose rifampicin by using pharmacokinetic-pharmacodynamic modeling and to predict the early bactericidal activity of 50 mg/kg rifampicin.

Methods Data included time to Mycobacterium tuberculosis positivity of liquid cultures of sputum specimens from 83 patients with tuberculosis who were treated with 10 mg/kg rifampicin (n = 8; reference arm) or 20, 25, 30, 35, or 40 mg/kg rifampicin (n = 15/arm) for 7 days. We used a semimechanistic time-to-event approach to model the time-to-positivity data. Rifampicin exposure and baseline time to culture positivity were explored as covariates.

Results The baseline time to culture positivity was a significant covariate on the predicted initial bacterial load, and rifampicin exposure was a significant covariate on the bacterial kill rate in sputum resulting in increased early bactericidal activity. The 90% prediction interval for the predicted median day 7 increase in time to positivity for 50 mg/kg rifampicin was 7.25–10.3 days.

Conclusions A significant exposure-response relationship was found between rifampicin exposure and early bactericidal activity. Clinical trial simulations showed greater early bactericidal activity for 50 mg/kg rifampicin.
Close

Details

Original languageEnglish
JournalJournal of Infectious Diseases
VolumeIn press
Early online date28 Apr 2018
DOIs
StateE-pub ahead of print - 28 Apr 2018

    Research areas

  • Pharmacodynamics, Tuberculosis, Pharmacokinetics, Patients, Time to positivity, Early bactericidal effect, Mycobacterium tuberculosis

Discover related content
Find related publications, people, projects and more using interactive charts.

View graph of relations

Related by author

  1. Toxicity associated with tuberculosis chemotherapy in the REMoxTB study

    Tweed, C. D., Crook, A. M., Amukoye, E. I., Dawson, R., Diacon, A. H., Hanekom, M., McHugh, T. D., Mendel, C. M., Meredith, S. K., Murphy, M. E., Murthy, S. E., Nunn, A. J., Phillips, P. P. J., Singh, K. P., Spigelman, M., Wills, G. H. & Gillespie, S. H. 11 Jul 2018 In : BMC Infectious Diseases. 18, 11 p., 317

    Research output: Contribution to journalArticle

  2. Moxifloxacin replacement in contemporary tuberculosis drug regimens is ineffective against persistent Mycobacterium tuberculosis: in the Cornell mouse model

    Liu, Y., Pertinez, H., Davies, G. R., Gillespie, S. H., Coates, A. R. & Hu, Y. Jul 2018 In : Antimicrobial Agents and Chemotherapy. 62, 7, 9 p., e00190-18

    Research output: Contribution to journalArticle

  3. Forecasting clinical dose-response from pre-clinical studies in tuberculosis research - translational predictions with rifampicin

    Wicha, S. G., Clewe, O., Svensson, R. J., Gillespie, S. H., Hu, Y., Coates, A. R. & Simonsson, U. S. 19 Jun 2018 In : Clinical Pharmacology & Therapeutics. Early View

    Research output: Contribution to journalArticle

  4. The potential for treatment shortening with higher rifampicin doses: relating drug exposure to treatment response in patients with pulmonary tuberculosis

    Svensson, E. M., Svensson, R. J., Te Brake, L. H. M., Boeree, M. J., Heinrich, N., Konsten, S., Churchyard, G., Dawson, R., Diacon, A. H., Kibiki, G. S., Minja, L. T., Ntingiya, N. E., Sanne, I., Gillespie, S. H., Hoelscher, M., Phillips, P. P. J., Simonsson, U. S. H. & Aarnoutse, R. 18 Jun 2018 In : Clinical Infectious Diseases. 67, 1, p. 34-41 8 p.

    Research output: Contribution to journalArticle

Related by journal

  1. Innovative Trial Designs Are Practical Solutions for Improving the Treatment of Tuberculosis

    Phillips, P. P. J., Gillespie, S. H., Boeree, M., Heinrich, N., Aarnoutse, R., McHugh, T., Pletschette, M., Lienhardt, C., Hafner, R., Mgone, C., Zumla, A., Nunn, A. J. & Hoelscher, M. 15 May 2012 In : Journal of Infectious Diseases. 205, p. S250-S257 8 p.

    Research output: Contribution to journalArticle

  2. Fragmented population structure of Plasmodium falciparum in a region of declining endemicity

    Anthony, T. G., Conway, D. J., Cox-Singh, J., Matusop, A., Ratnam, S., Shamsul, S., Singh, B. & Cox Singh, J. 1 May 2005 In : Journal of Infectious Diseases. 191, 9, p. 1558-1564 7 p.

    Research output: Contribution to journalArticle

  3. Iron Regulates Hepatitis C Virus Translation via Stimulation of Expression of Translation Initiation Factor 3

    Theural, I., Zoller, H., Obrist, P., Datz, C., Bachmann, F., Elliott, R. M. & Weiss, G. 15 Aug 2004 In : Journal of Infectious Diseases. 190, 4, p. 819-825 7 p.

    Research output: Contribution to journalArticle

Related by journal

  1. Strategies and challenges involved in the discovery of new chemical entities during early-stage tuberculosis drug discovery

    Coxon, G., Cooper, C., Gillespie, S. H. & McHugh, T. Mar 2012 Journal of Infectious Diseases, supplement, p. S1-7 8 p.

    Research output: Contribution to specialist publicationArticle

ID: 253233657